Eligibility and implementation of rivaroxaban for secondary prevention of atherothrombosis in clinical practice-insights from the CANHEART study
Sheth MS, Yu B, Chu A, Porter J, Tam DY, Ferreira-Legere LE, Goodman SG, Farkouh ME, Ko DT, Abdel-Qadir H, Udell JA. J Am Heart Assoc. 2022; 11(24):e026553. Epub 2022 Dec 14.